Construction and application of infectious clone of attenuated FJzz1 strain of porcine epidemic diarrhea virus
Through a reverse genetic system based on in vitro ligation means, the PEDV genome is divided into small fragments and genetic markers are introduced, which solves the stability and transcriptional heterogeneity of PEDV full-length infectious cDNA clones, and achieves efficient rescue and identification, providing A platform for the development of new vaccines and antiviral drugs.
Patent Information
- Application Number
- CN202310916062.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-07-25
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2043-07-25
AI Technical Summary
The prior art is difficult to effectively clone and study full-length infectious cDNA of swine epidemic diarrhea virus (PEDV), mainly due to the large genome, instability of replicase sequences, and in vitro transcriptional heterogeneity, and difficulty in vaccine identification.
Using a reverse genetic system based on in vitro ligation means, the PEDV genome was divided into 7 small fragments, and in vitro transcription was performed through T7 and SP6 prokaryotic promoters. The pBSK vector was constructed by ligating specific restriction enzyme cleavage sites. , the genetic marker XmaI restriction enzyme cleavage site was introduced to improve clonal stability and rescue efficiency.
It has achieved stable preservation and efficient rescue of the full-length genome of PEDV, reduced the instability of toxic fragments, improved the efficiency of virus packaging, and facilitated differential diagnosis through genetic markers, providing a development platform for new vaccines and antiviral drugs.
Smart Images

Figure CN116904512B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of reverse genetics of porcine epidemic diarrhea virus, and in particular to a reverse genetics system for rescuing porcine epidemic diarrhea virus FJzz1 strain based on in vitro ligation means. Background Art
[0002] Porcine epidemic diarrhea is an acute, highly contagious enteric disease of pigs, caused by porcine epidemic diarrhea virus (PEDV). The disease is characterized by acute enteritis, vomiting, watery diarrhea and loss of appetite. Pigs of all ages are susceptible, but newborn piglets are the most seriously affected, with an morbidity and mortality rate of up to 90%-100%. The disease has become one of the major infectious diseases that seriously endanger the pig industry. At present, the PEDV prevalent in Asia and America is mainly the G2 gene subtype strain, accounting for more than 90%, posing a huge threat to the global pig industry.
[0003] Reverse genetics technology provides a powerful tool for comprehensive research on the genome structure, gene function, protein expression and regulation, viral pathogenic mechanism and development of new vaccines of PEDV. However, the infectious clone of PEDV was not reported for the first time until 2013. There are two main reasons: First, the genome of PEDV is huge (about 28Kb), and there is no suitable cloning vector to accommodate the full-length cDNA molecule; the other main reason is that some replicase sequences in the PEDV genome are unstable in the bacterial cloning system and are prone to mutations such as recombination. Based on the above two main reasons, it is difficult to study PEDV using traditional reverse genetics technology. Therefore, researchers have developed non-traditional reverse genetics technology on this basis, mainly including targeted RNA recombination technology and construction of full-length infectious cDNA clones. Targeted RNA recombination technology is the earliest established coronavirus reverse genetics operation technology. It allows researchers to transform 1 / 3 of the genome, including all structural protein genes, auxiliary protein genes and 3' non-coding regions at the 3' end of the coronavirus. However, targeted RNA recombination technology also has defects. It cannot transform the 5' non-coding region and replicase gene of the coronavirus, thus limiting its development.
[0004] The construction method of the current coronavirus full-length cDNA infectious clone mainly contains bacterial artificial chromosome system (BAC system) and in vitro cDNA ligation method.But at present, there are still some problems that hinder the construction of coronavirus full-length infectious cDNA clone, such as the genome of coronavirus is very large (27-32kb), conventional technology is difficult to operate, some replicase gene cDNA clones have instability in bacteria, and the transcript obtained in vitro has heterogeneity, etc. And the restriction site selection is more restricted in the conventional method, and multiple large fragments are subjected to restriction ligation in vitro with low efficiency, which is difficult to be applied to the construction of other strains full-length infectious clones.In addition, the T7 promoter added is utilized, and the transcript obtained by in vitro transcription has heterogeneity, and the virus rescue efficiency is low.The vaccine prepared by the prior art is in use, particularly when distinguishing vaccine strain immunity from wild strain infection, and detection and identification are difficult, and the workload is large and the time-consuming is long.
[0005] In contrast, for coronaviruses with large genomes, the in vitro cDNA ligation method is used to construct viral infectious clones. It only requires cloning of individual small fragments in bacteria, without cloning the full-length cDNA of the viral genome in bacteria. This avoids technical defects such as unstable cloning of toxic fragments in bacteria and difficulty in obtaining full-length viral genome clones. This method simplifies the operating procedures for obtaining full-length cDNA of the viral genome and facilitates the construction of viral infectious clones. Summary of the invention
[0006] In view of the deficiencies in the prior art, the present invention establishes a reverse genetics system for rescuing the porcine epidemic diarrhea virus FJzz1 strain based on in vitro ligation, which overcomes the problem in the prior art that the cDNA clone of the partial replicase gene of the coronavirus cannot be stably preserved in bacteria, overcomes the problem of low efficiency of traditional enzyme cutting and ligation, and also overcomes the problem of transcript heterogeneity caused by in vitro transcription.
[0007] At the same time, since the F200 generation strain of FJzz1 rescued by the system in the present invention has significantly weakened pathogenicity to piglets, the strain has a low replication level in piglets and cannot cause obvious pathological damage to intestinal tissues. Moreover, the F200 generation strain of FJzz1 can induce the piglet body to produce high levels of type I interferon and type III interferon, and has the potential for development as a PEDV attenuated live vaccine. At the same time, the weak strain is obtained by weakening the strong toxin of PEDV FJzz1 through in vitro passage, has strong cell adaptability, and its genome has genetic stability. In particular, in the present invention, we introduced the genetic marker Xma I restriction enzyme cleavage site into the strain through silent mutation. The molecular marker can be stably inherited, which is convenient for differential diagnosis with naturally infected PEDV wild toxins. Using conventional infectious cloning technology, due to the complex operating procedures, it is easy to cause some new gene mutations, which makes it difficult to ensure the fidelity of typical gene characteristics such as the deletion of two consecutive amino acids and the disappearance of an N-linked glycosylation site in the S protein of the F200 generation attenuated strain of FJzz1. It may also change the biological characteristics of the attenuated strain.
[0008] Specifically, the present application provides a reverse genetics system for rescuing porcine epidemic diarrhea virus FJzz1 strain based on in vitro ligation, the system comprising:
[0009] (a) The modified vector pBSK. Further, the vector pBSK is obtained by modifying the multiple cloning site region (MCS) between Kpn I and Sac I in the plasmid pBluescript II SK(+), wherein the modified multiple cloning site region (MCS) is specifically: Kpn I-Sac II-BamH I-Avr II-Pac I-Xma I-Blp I-Age I-Asc I-SacI.
[0010] (b) The full-length PEDV genome consists of seven fragments, namely: A, B, C, D, E, F and G, with different sizes (corresponding to Genbank number, MK288006.1, and corresponding specific positions: A (1-3497nt), B (3497-9503nt), C (9503-13014nt), D (13014-16224nt), E (16224-20712nt), F (20712-25571nt), G (25571-28035nt)). These seven fragments are connected by six specific restriction endonuclease sites, namely BamHⅠ, AvrⅡ, PacⅠ, Xma I, BlpⅠ and AgeⅠ. Furthermore, a T7 prokaryotic promoter was added to the 5' end of the A fragment; 23 poly A tails were added to the 3' end of the G fragment; and the restriction endonuclease cleavage site Xma I between the D fragment and the E fragment was a genetic maker introduced by silent mutation.
[0011] Further preferably, the seven segments of the full length of the PEDV genome are integrated into three large segments, AB, CDE and FG, and further, a T7 prokaryotic promoter is added to the 5' end of the AB segment for subsequent in vitro transcription. At the same time, in order to improve the packaging efficiency of the rescued virus, a tail consisting of 23 poly A is added to the 3' end of the FG segment.
[0012] (c) a helper plasmid containing the N gene of porcine epidemic diarrhea virus (wherein the specific sequence of the N gene is Genbank No.: MK288006.1, corresponding to the specific position 26376-27701 nt),
[0013] The present invention further provides a method for rescuing the porcine epidemic diarrhea virus FJzz1 strain, comprising the following steps: co-transfecting the recombinant expression vector and the auxiliary plasmid in the system into host cells, repeatedly freezing and thawing after cell pathological changes, and collecting the supernatant to obtain the rescued virus.
[0014] The present invention also provides the rescued virus obtained by the method.
[0015] The present invention also provides an application of the rescued virus, wherein the application is:
[0016] Application in the creation of new marker vaccines for porcine epidemic diarrhea virus;
[0017] Application in screening of drugs against porcine epidemic diarrhea virus;
[0018] Application in the study of the pathogenesis of porcine epidemic diarrhea virus;
[0019] Or its application in the study of porcine epidemic diarrhea virus gene function.
[0020] Beneficial Effects
[0021] The PEDV reverse genetics operating system provided by the present invention provides a powerful tool for comprehensive research on the genome structure, gene function, protein expression and regulation, viral pathogenic mechanism and development of new vaccines of PEDV. It has the advantages of large capacity, low copy and high replication rigor, and can ensure the stable preservation of large fragment genome sequences of PEDV in bacteria.
[0022] The present invention is first analyzed by its whole genome, and on the basis of the restriction endonuclease enzyme cutting site unique in its whole genome, we divide it into seven fragments of different sizes, A, B, C, D, E, F and G. Subsequently, in order to improve the subsequent connection efficiency, we integrate these seven small fragments into three large fragments, AB, CDE and FG, and add a T7 prokaryotic promoter at the 5' end of the AB fragment for subsequent in vitro transcription. At the same time, in order to improve the packaging efficiency of the rescued virus, a tail composed of 23 poly A is added at the 3' end of the FG fragment. In addition, according to the degeneracy principle of amino acid codons, a genetic marker is introduced between the D fragment and the E fragment by the method of silent mutation, and it is also a restriction endonuclease enzyme cutting site Xma I, and these two characteristics can be used to distinguish the rescued virus from the parent strain. By homologous recombination technology, the three large fragments of AB, CDE and FG are constructed into the transformed cloning vector pBSK respectively, and three cloning plasmids of pBSK-AB, pBSK-CDE and pBSK-FG are constructed. It is worth noting that by dividing the full-length cDNA into three large fragments, especially the two large fragments AB and CDE, the toxic fragments of PEDV (replicase gene) can be separated, thereby avoiding the instability caused by the toxic fragments in the full-length cDNA of PEDV during the proliferation of E. coli, thereby improving the efficiency of rescuing the virus.
[0023] Subsequently, the three cloned plasmids pBSK-AB, pBSK-CDE and pBSK-FG were double-digested, and the respective AB, CDE and FG target fragments were recovered. According to the sticky ends produced by the same restriction endonuclease between the fragments, the three large fragments AB, CDE and FG were connected into full-length cDNA clones under the action of T4 ligase. After phenol-chloroform extraction, the full-length cDNA was in vitro transcribed into RNA transcripts using a T7 in vitro transcription kit. At the same time, a pBSK-N cloned plasmid was constructed, and an SP6 prokaryotic promoter was added before the start codon of the N gene. After the pBSK-N cloned plasmid was linearized by single restriction digestion, the N gene was in vitro transcribed into RNA transcripts using an SP6 in vitro transcription kit, and transfected into Vero cells together with the in vitro RNA transcripts of the full-length cDNA. The results showed that when rescuing the virus, the transfection efficiency of the rescued virus could be significantly improved by simultaneously transfecting the N gene transcripts of PEDV and the in vitro RNA transcripts of the full-length cDNA.
[0024] Since the PEDV genome is relatively large, about 28kb, we used the electroporation method to electrotransfect the above two RNA transcripts into Vero cells for virus rescue. The results showed that 36h after transfection, obvious cytopathic effects could be observed on Vero cells. The first generation of rescued viruses was collected and continued to be propagated in Vero cells to the 20th generation. RT-PCR and sequencing results showed that the introduced genetic marker Xma I was stably present during the passage process. Analysis of the biological characteristics of the rescued virus showed that the replication level and plaque size of the rescued virus were similar. The above results fully demonstrate that we have successfully obtained a stable and genetically marked rFJzz1 attenuated infectious clone strain through the in vitro ligation method, which provides a technical platform for subsequent research on the pathogenic mechanism of FJzz1 strain PEDV and the development of new vaccines.
[0025] The virus rescue system of the present invention is not only conducive to further experimental research on the pathogenic mechanism and gene function of PEDV, but also has very important application value in antiviral drug screening and vaccine development. The obtained infectious clone strain has a genetic marker Xma I, which can be stably inherited and can be used for differential diagnosis from naturally infected PEDV wild virus. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 Schematic diagram of pBluescript II SK(+) vector transformation, wherein: A: pBluescript II SK(+) vector map; B: schematic diagram of restriction sites of the transformation sequence; C: schematic diagram of primers for transformation vector identification; D: PCR identification of the transformation vector.
[0027] Figure 2Schematic diagram of the full-length cDNA segmentation design of the FJzz1 attenuated strain.
[0028] Figure 3 The diagrams show the amplification results of the three major target fragments and their respective linearized vectors, where A: AB fragment and its linearized vector amplification; B: CDE fragment and its linearized vector amplification; C: FG fragment and its linearized vector amplification.
[0029] Figure 4 Identification result diagrams were constructed for three large fragment plasmids, where A: pBSK-AB plasmid identification; B: pBSK-CDE plasmid identification; C: pBSK-FG plasmid identification.
[0030] Figure 5 This is the identification result of pBSK-N plasmid.
[0031] Figure 6 Schematic diagram of the construction of full-length cDNA infectious clone.
[0032] Figure 7 For virus rescue and identification, A: The first-generation rescued virus causes cytopathic effect 18 hours after infecting Vero cells; B: The second-generation rescued virus causes cytopathic effect 18 hours after infecting Vero cells; C: The rescued virus is subjected to indirect immunofluorescence staining with PEDV N protein monoclonal antibody to show the plaque morphology of the rescued virus; D: Schematic diagram of genetic marker enzyme digestion identification; E: Genetic marker single enzyme digestion identification; F: Genetic marker sequencing identification.
[0033] Figure 8 Identification of genetic markers for virus rescue.
[0034] Fig. 9 For the analysis of the in vitro biological characteristics of the rescued virus, A: The rescued virus caused cytopathic effects 18 hours after infecting Vero cells; B: The rescued virus was subjected to indirect immunofluorescence staining with a monoclonal antibody against the PEDV N protein; C: The plaque morphology of the rescued virus; D: The growth curve of the rescued virus. DETAILED DESCRIPTION
[0035] The specific implementation modes of the present invention are described in detail below in conjunction with the accompanying drawings, but it should be understood that the protection scope of the present invention is not limited by the specific implementation modes.
[0036] Unless explicitly stated otherwise, throughout the specification and claims, the term “comprise” or variations such as “include” or “comprising”, etc., will be understood to include the stated elements or components but not to exclude other elements or components.
[0037] Material preparation
[0038] Main reagents
[0039] Cell culture medium DMEM, 0.25%-EDTA trypsin, fetal bovine serum FBS, PBS, anti-mouse fluorescent secondary antibody Alexa 488donkey anti-mouse IgG(H+L)antibody(Invitrogen TM ) and Revert Aid FirstStrand cDNA Synthesis Kit were purchased from Life Technologies; Trypsin was purchased from Sigma; RNA extraction kit RNeasy Mini Kit was purchased from Qiagen; plasmid mini-extraction kit and PCR product gel recovery kit were purchased from OMEGA; plasmid midi-extraction kit was purchased from MACHEREY-NAGEL; High-Fidelity DNA Polymerase, restriction endonucleases and T4 DNA ligase were purchased from NEB; In- HD Cloning Kit and LA Taq Premix were purchased from TaKaRa; pBluescript II SK(+) plasmid was preserved by our laboratory.
[0040] Main instruments
[0041] The main instruments used in this study include: PCR instrument, UV gel imaging system, biological safety cabinet, cell culture incubator, inverted fluorescence microscope, 4℃ low-temperature centrifuge, 4℃ refrigerator, -80℃ ultra-low temperature refrigerator, American Bio-rad Gene PulserXcell electroporation system, etc.
[0042] Example 1 pBluescript II SK(+) vector modification
[0043] An important factor in constructing viral infectious clones is that the copy number of the vector used for gene cloning in E. coli should be low, because high-copy vectors are unstable during the proliferation of E. coli, which will cause the full-length viral genome cDNA clone to easily undergo gene mutations, deletions, and insertions, causing the viral cDNA clone to lose authenticity. At the same time, the gene cloning vector must contain the necessary multiple cloning sites required for gene cloning to facilitate the cloning of large genomes or complex full-length viral gene cDNAs. The commercialized pBluescript II SK(+) is a low-copy plasmid that can meet the needs of cloning large viral gene fragments, but the multiple cloning enzyme sites (MCS) in many commercial vectors, including the pBluescript II SK(+) vector, are commonly used restriction enzyme sites. These enzyme sites are not unique in the viral genome. Therefore, when using these commercial vectors to construct cDNA clones, it is easy to cause gene fragment splicing errors, resulting in chaotic arrangement of viral genome sequences. It is difficult to use these conventional enzyme sites to obtain correct infectious cDNA clones, which increases the difficulty of obtaining correct clones. Therefore, in order to improve the efficiency of obtaining correct gene cloning, increase the fidelity of the viral cDNA clone obtained, it is necessary to transform the multiple cloning restriction site (MCS) of pBluescriptII SK (+) according to the restriction site feature contained in the F200 generation viral genome sequence of FJzz1, so as to improve the efficiency and authenticity of viral genome cDNA clone. For this reason, the present invention needs to carry out vector transformation to pBluescript II SK (+).
[0044] According to the restriction endonuclease cleavage site analysis of the whole genome sequence of the FJzz1 attenuated strain PEDV, the multiple cloning site region (MCS) between Kpn I and Sac I in the plasmid pBluescript II SK(+) was modified for subsequent construction of full-length cDNA infectious clones. The synthetic modified sequence was replaced by restriction endonuclease Kpn I and Sac I in the pBluescript II SK(+) vector The multiple cloning site sequence (see Figure 1 ).
[0045] Synthesis of modified sequences
[0046] According to the designed restriction site sequence, the following single-stranded sequence and its reverse complementary sequence were synthesized by Shanghai Invitrogen Biotechnology Co., Ltd.: GGTACCCCGCGGGGATCCCCTAGGTTAATTAACCCGGGGCTCAGCACCGGTGGCGCGCC GAGCTC (SEQ ID NO. 1). After dissolution, equal amounts of the single-stranded sequence and its reverse complementary sequence were taken in 1.5 mL centrifuge tubes, placed in a pre-prepared 98°C water bath, and naturally cooled to room temperature to obtain a double-stranded modified sequence, which was stored at -20°C for later use.
[0047] pBluescript II SK(+) plasmid digestion and recovery
[0048] Take 2 μg of plasmid pBluescript II SK(+) and perform double digestion with restriction endonucleases Kpn I and Sac I. The digestion system is as follows:
[0049]
[0050] After incubation in a 37°C water bath for 3 hours, 0.8% agarose nucleic acid gel electrophoresis was performed, and the gel was excised and recovered using the gel recovery kit of OMEGA Company according to the instructions, and stored at -20°C for future use.
[0051] Preparation of transformation vector
[0052] Take the pBluescript II SK(+) linearized fragment and the modified sequence recovered after enzyme digestion, mix them at a ratio of 1:10, and connect them at 16°C overnight under the action of T4 ligase. Transform the Top 10 competent cells with the ligation product and plate them on ampicillin-resistant LB solid medium. Incubate in an incubator at 37°C for 16 hours, pick 12 monoclonal colonies and place them in ampicillin-resistant LB liquid medium, and shake and culture them at 37°C for 3 hours.
[0053] PCR identification of transformed vector
[0054] The above 12 monoclonal bacterial suspensions were taken respectively and PCR identification was performed using LA Taq Premix of TaKaRa Company. The PCR system was as follows (MCS-F and MCS-R sequences are shown in Table 1):
[0055]
[0056] The PCR products were subjected to 0.8% agarose gel electrophoresis. The positive bacterial solution was continued to be cultured on a shaker at 37°C for 12 hours. After the bacteria were incubated, the plasmid was extracted using the plasmid extraction kit of OMEGA according to the instructions and sent to Shanghai Invitrogen Biotech Co., Ltd. for first-generation sequencing. The results of the bacterial solution PCR showed that all 12 monoclonal colonies were positive, while the pBluescript II SK(+) vectors were negative. After further verification by sequencing, the sequences of the 12 selected monoclonal colonies were completely correct, indicating that these 12 monoclonal colonies were successfully transformed and can be used for the construction of subsequent infectious clones. The correctly transformed vector was named pBSK.
[0057] Example 2 Design and synthesis of full-length genome segments of FJzz1 attenuated strain
[0058] In order to facilitate the subsequent acquisition of the full-length cDNA of PEDV with a genome of about 28Kb, simplify the operation procedure of dividing the genome into too many small gene fragments for frequent cloning and splicing, and avoid the adverse factors such as gene mutation, deletion and insertion caused by frequent cloning of too many gene fragments, we divided the whole genome of the FJzz1 weak strain into 7 fragments of different sizes, A, B, C, D, E, F and G, based on the restriction endonuclease cleavage site analysis of the whole genome sequence of the FJzz1 weak strain. The size of these 7 gene fragments can ensure the high efficiency of amplification using high-fidelity DNA polymerase, and at the same time have strong specificity. It also avoids the unstable factors of potential toxic sequences in the viral genome in the bacterial cloning system, and improves the efficiency of gene cloning. In addition, the 7 fragments were designed to be connected by 6 specific restriction endonuclease cleavage sites unique to the genome, such as BamHⅠ, AvrⅡ, PacⅠ, Xma I, BlpⅠ and AgeⅠ (see Figure 2 ), which facilitates the subsequent homologous recombination into three large fragments. At the same time, a T7 prokaryotic promoter was added to the 5' end of the A fragment, and it was connected to the transformation vector pBSK with a SacⅡ restriction site; 23 poly A tails were added to the 3' end of the G fragment, and it was connected to the transformation vector pBSK with an Asc I restriction site. In addition, the restriction endonuclease cleavage site Xma I between the D and E fragments is a genetic maker introduced by silent mutation, which is used for the subsequent identification of rescued viruses.
[0059] Primer design and synthesis
[0060] Since the PEDV genome is relatively large, approximately 28Kb, its full-length 7 fragments are further divided into three large fragments, AB, CDE and FG, and the three large fragments are homologously recombined into the transformation vector pBSK by homologous recombination. Therefore, when designing primers, upstream homology arms and downstream homology arms are added to the 5' and 3' ends of the 7 fragments, respectively, and a T7 promoter sequence is added to the 5' end of the A fragment, and a poly A (23A) tail is added to the 3' end of the G fragment. At the same time, when designing primers for N gene amplification, an SP6 promoter sequence is added to its 5' end, and a poly A (23A) tail is added to its 3' end. All primers were synthesized by Invitrogen, and the sequences are as follows:
[0061] Table 1 Primer sequences used in this study
[0062]
[0063] Amplification of 7 fragments of the full-length gene and the modified vector
[0064] The cDNA of FJzz1 attenuated PEDV strain (Chen P, Zhao X, Zhou S, Zhou T, Tan X, Wu X, Tong W, Gao F, Yu L, Jiang Y, Yu H, Yang Z, Tong G, Zhou YA Virulent PEDV Strain FJzz1 with Genomic Mutations and Deletions at the High Passage Level Was Attenuated in Piglets via Serial Passage In Vitro. Virol Sin. 2021 Oct; 36(5): 1052-1065. doi: 10.1007 / s12250-021-00368-w.) and the transformed vector pBSK were used as templates, and the above primers were used as specific primers. High-Fidelity DNA Polymerase was used to amplify seven fragments A, B, C, D, E, F and G with different homology arms, N gene fragments, and three linearized vectors. The amplification system is as follows (the F and R sequences are shown in Table 1):
[0065]
[0066]
[0067] The PCR reaction procedure is as follows:
[0068]
[0069] The results of agarose gel electrophoresis showed that seven fragments with different homology arms and three linearized vector fragments were successfully amplified. The target fragments had good specificity and the sizes were consistent with expectations (see Figure 3 The PCR product was subjected to 0.8% agarose nucleic acid gel electrophoresis, and then purified using the OMEGA gel recovery kit according to the operating instructions. The purified product was measured for concentration and stored at -20°C for later use.
[0070] Construction of three large fragment plasmids by homologous recombination
[0071] Using TaKaRa's In- HD Cloning Kit, according to the user manual, homologously recombined the three large fragments AB, CDE and FG into the transformation vector pBSK, and constructed three large fragment plasmids, namely pBSK-AB, pBSK-CDE and pBSK-FG. The systems are as follows:
[0072] pBSK-AB:
[0073]
[0074] pBSK-CDE:
[0075]
[0076] pBSK-FG:
[0077]
[0078]
[0079] Note: The optimal amount of cloning vector used = (0.02 × number of vector base pairs) ng;
[0080] The optimal amount of insert fragment used = (0.04 × number of base pairs of insert fragment) ng.
[0081] If the system is >10μL, double the volume of 5X In-Fusion HD Enzyme Premix and add water to make up to 20μL.
[0082] The reaction conditions are as follows: 50℃ water bath for 15min, and stand on ice for 2min. The reaction product can be directly used to transform into Tiangen's Top 10 competent cells, or stored at -20℃.
[0083] Identification of positive colonies and plasmid extraction
[0084] Several monoclonal colonies were picked and placed in ampicillin-resistant LB liquid culture medium, and after shaking and culturing at 37°C for 3 hours, PCR identification of the bacterial solution was performed using LA Taq Premix from TaKaRa. The PCR system is as follows:
[0085]
[0086] (The F and R sequences are shown in Table 1)
[0087] The PCR products were subjected to 0.8% agarose gel electrophoresis to identify positive colonies.
[0088] The positive bacterial solution that was correctly identified was continued to be cultured in a shaking incubator at 37°C for 12 hours, and the bacteria were preserved at a final glycerol concentration of 15-20%. The remaining bacterial solution was used to extract plasmids using the OMEGA plasmid extraction kit according to the instructions, and sent to Shanghai Invitrogen for first-generation sequencing verification. The PCR identification results of the bacterial solution showed that the three large fragment plasmids pBSK-AB, pBSK-CDE and pBSK-FG were successfully constructed, and the double enzyme digestion identification results showed that these four plasmids could be cut by specific restriction endonucleases, and the sizes of the three large fragments AB, CDE and FG obtained were all correct, consistent with expectations (see Figure 4 ). The plasmids that were correctly identified by bacterial liquid PCR and restriction digestion were sequenced by Shanghai Invitrogen, and the results were completely correct.
[0089] In the same way, the N gene fragment recovered by PCR was homologously recombined into the modified vector pBSK to construct the pBSK-N plasmid. The results of bacterial liquid PCR identification showed that the picked monoclonal colonies were all positive, and the results of single and double enzyme digestion identification showed that the pBSK-N plasmid could be cut by restriction endonucleases KpnⅠ and BamHⅠ, which was consistent with expectations (see Figure 5 ). In addition, the plasmids with correct bacterial liquid PCR and enzyme digestion identification were sent to Shanghai Invitrogen for sequencing, and the results were completely correct. The above results show that the pBSK-N plasmid was successfully constructed.
[0090] The positive bacterial solution verified by sequencing was transferred to 200mL of ampicillin-resistant LB liquid medium at a ratio of 1:100, and after shaking and culturing at 37°C for 16 hours, the plasmid was extracted using the plasmid extraction kit of Macherey-Nagel according to the operating instructions. The restriction endonucleases of NEB were used to double-digest the three plasmids pBSK-AB, pBSK-CDE and pBSK-FG and recover the target fragments. The restriction digestion systems of the three plasmids are as follows:
[0091] pBSK-AB:
[0092] pBSK-CDE:
[0093]
[0094] pBSK-FG:
[0095]
[0096] Reaction conditions: 37°C water bath for 3h. The digestion products were subjected to 0.8% agarose gel electrophoresis, and the three large linear fragments AB, CDE and FG were recovered using the gel recovery kit of OMEGA Company, and the concentration was measured and stored at -20°C for future use.
[0097] Full-length cDNA in vitro ligation
[0098] Using the in vitro ligation method, the three large linear fragments AB, CDE and FG were collected and mixed in equimolar proportions. Under the action of T4 ligase, the AB fragment and the CDE fragment were connected through AvrⅡ, while the CDE fragment and the FG fragment were connected through BlpⅠ (see Figure 6 ). Finally, the three large linear fragments AB, CDE and FG were connected to form linearized ABCDEFG, and after phenol-chloroform extraction and purification, the full-length cDNA was obtained. The connection system is as follows:
[0099]
[0100] Ligation reaction conditions: 16°C overnight, and the ligation product was purified by phenol-chloroform extraction.
[0101] In vitro transcription
[0102] The purified full-length cDNA ligation product was transcribed in vitro using the mMESSAGE mMACHINE T7 Transcription Kit according to the operating instructions; at the same time, the N gene fragment was transcribed in vitro using the mMESSAGE mMACHINE SP6 Transcription Kit to obtain the N transcript. The transcription system is as follows:
[0103] Full-length cDNA (T7):
[0104]
[0105] N(SP6):
[0106]
[0107] Reaction conditions: 40.5°C, 25 min; 37°C, transcription 60 min; 40.5°C, 25 min.
[0108] Example 3 Virus rescue and identification
[0109] Virus rescue
[0110] The full-length cDNA transcript and the N gene transcript were co-transfected into Vero cells using the Gene Pulser Xcell electroporation system of Bio-rad to rescue the virus. The specific operation is as follows:
[0111] 1) After a bottle of T75 Vero cells has grown to full size, add 3 mL of Trypsin, digest at 37°C for 2 min, and discard the Trypsin;
[0112] 2) Tap the cell bottle gently, add 10 mL of DMEM containing 10% FBS to blow the cells, and transfer to a 15 mL centrifuge tube;
[0113] 3) Centrifuge at 1000 rpm for 5 min at 4°C and discard the culture medium;
[0114] 4) Resuspend the cells with 10 mL of cold PBS, centrifuge at 1000 rpm for 5 min at 4°C, and discard the supernatant;
[0115] 5) Repeat step 4);
[0116] 6) Resuspend the cells with 800uL cold PBS, add the full-length cDNA transcript and N gene transcript, mix thoroughly, and transfer to the electroporation cup;
[0117] 7) Set the Gene Pulser Xcell to 450V, 50μF, and perform three consecutive electric shocks (with 10s intervals, do not disturb the cells);
[0118] 8) After standing at room temperature for 10 min, transfer to a 15 mL centrifuge tube containing 12 mL of 10% FBSDMEM, mix thoroughly and spread on a six-well plate;
[0119] 9) Culture in a 37°C, 5% CO2 incubator for 4 h to allow the cells to adhere;
[0120] 10) After 4 h, the medium was changed to DMEM without FBS (with a small amount of trypsin), and after 12 h, trypsin was added to a final concentration of 10 μg / mL;
[0121] 11) Culture in a 37°C, 5% CO2 incubator for 2-4 days and observe CPE.
[0122] Identification of rescued viruses
[0123] The rescued virus needs to be further validated to ensure that CPE is caused by the rescued virus and not the parental strain. The specific steps are as follows:
[0124] 1) When most cells showed cytopathic effects, the six-well plate was placed in a -80°C refrigerator for 1 hour, and then frozen and thawed once at room temperature to obtain the first-generation virus rFJ200-F1, which was then stored in a -80°C refrigerator after aliquoting;
[0125] 2) Take 100 μL of the first-generation virus solution, dilute it in 3 mL DMEM (final concentration of trypsin 10 μg / mL), inoculate it into T25 Vero cells, and incubate it at 37°C, 5% CO2 for 1 hour; wash the cells twice with PBS, replace it with 5 mL DMEM (final concentration of trypsin 10 μg / mL), and incubate it at 37°C, 5% CO2 for 24-36 hours to observe CPE;
[0126] 3) When most cells show cytopathic effects, collect the second-generation virus rFJ200-F2 and store it in aliquots;
[0127] 4) Take an appropriate amount of the second-generation virus solution, inoculate Vero cells according to the above method, and perform IFA identification;
[0128] 5) Take another 100 μL of the second-generation virus solution and use the RNeasy Mini Kit to extract RNA according to the instructions in the manual;
[0129] 6) Reverse transcribe RNA into cDNA using Revert Aid First Strand cDNA Synthesis Kit;
[0130] 7) Using cDNA as template and XmaI-F / XmaI-R as primers, PCR amplification was performed using LA Taq Premix from TaKaRa (50 μL system);
[0131] 8) Take 5 μL of PCR product for XmaI single enzyme digestion identification, and send the remaining PCR product to a sequencing company for sequencing verification.
[0132] The results confirmed that the in vitro ligated full-length cDNA was transcribed into RNA transcripts using the T7 in vitro transcription kit. The full-length cDNA transcripts and N gene transcripts were then co-transfected into Vero cells using the Gene Pulser Xcell electroporation system from Bio-rad to rescue the virus. The results showed that obvious CPE could be observed around 36 hours after transfection (see Figure 7). After the cells were completely diseased, the first-generation virus was collected and named rFJzz1-F1. When rFJzz1-F1 was re-infected with Vero cells, typical CPE could still be observed. IFA results showed that Vero cells infected with the second-generation rescued virus rFJzz1-F2 using the anti-PEDV N protein mouse monoclonal antibody prepared in this laboratory as the primary antibody could observe specific green fluorescence under an inverted fluorescence microscope. In addition, according to the principle of amino acid degeneracy, a genetic marker was introduced at position 16244 of the FJzz1 attenuated strain genome through silent mutation, which was also a restriction enzyme site Xma I. The genetic marker was completely correct after Xma I single enzyme digestion identification and sequencing verification, indicating that the PEDV FJzz1 attenuated infectious clone strain rFJzz1 strain was successfully rescued.
[0133] Genetic stability analysis of rescued viruses
[0134] According to the above method, the rescued virus was blindly propagated in vitro on Vero cells to the 20th generation (rFJzz1-F20). rFJzz1-F5, rFJzz1-F10 and rFJzz1-F20 viruses were selected, and the total RNA was extracted and reverse transcribed into cDNA. The cDNA of the rescued viruses of different generations was used as a template and PCR amplification was performed with XmaⅠ-F / Xma IR as primers. The PCR amplification products were identified by XmaⅠ single enzyme digestion and sequenced for verification. The results showed that the PCR products amplified with XmaⅠ-F / Xma IR as primers could be completely cut by the restriction endonuclease XmaⅠ, and the sequencing results showed that the introduced genetic marker XmaⅠ sequence was completely correct (see Figure 8 ). The above results fully demonstrate that the genetic markers we introduced during the construction of this infectious clone can stably exist as the virus is propagated in vitro.
[0135] Plaque assay for rescued viruses
[0136] Select rFJzz1-F5, rFJzz1-F10 and rFJzz1-F20 viruses for plaque assay. First, take six 1.5mL EP tubes and add 0.9mL DMEM (trypsin concentration is 10μg / mL) to each tube. Add 0.1mL of virus liquid supernatant to the first tube, vortex and mix well, take 0.1mL and add it to the second tube for 10-fold gradient dilution. Then, add 1mL of virus dilution to six-well plates covered with a single layer of Vero cells. After incubation at 37°C for 1 hour, wash the six-well plates three times with PBS, and add 3mL of pre-prepared liquid low-melting-point agarose solution containing 10μg / mL trypsin to each well. After being placed at room temperature for 2 hours until the agar is completely solidified, the six-well plates are placed at 37°C for incubation. When the spots become large enough and clearly visible under a microscope and the naked eye, crystal violet staining is performed.
[0137] Indirect immunofluorescence of rescued viruses
[0138] Take appropriate amount of rFJzz1-F5, rFJzz1-F10 and rFJzz1-F20 viruses and inoculate them into Vero cells. When the cells show obvious CPE, fix them with 80% cold ethanol at 4℃ for 1 hour. After washing twice with PBS, add the diluted anti-PEDV N protein monoclonal antibody primary antibody to the corresponding wells and incubate at 37℃ for 1 hour. After washing three times with PBS, add FITC-labeled donkey anti-mouse IgG (1:800 dilution) as the secondary antibody to the cells incubated with monoclonal antibodies. After incubation at 37℃ for 1 hour, wash three times with PBS and observe under a fluorescence microscope.
[0139] Saving the virus' growth curve
[0140] The rFJzz1-F5, rFJzz1-F10 and rFJzz1-F20 viruses were selected for growth curve determination. First, the virus was inoculated into a 96-well plate at 0.01 MOI, and the cell culture supernatant was collected at 6h, 12h, 18h, 24h, 30h and 36h after inoculation. The virus titers of these samples were then measured by the tissue culture infection half count (TCID 50 ) determination, the steps are as follows: first, the sample is diluted 10 times (10 -1 -10 -8 ), then inoculate the diluted virus solution of different concentrations into a 96-well plate covered with a monolayer of Vero cells, and inoculate each diluted virus solution into 8 vertical cell culture wells from left to right, and culture them in a 37°C cell culture incubator for 4-5 days, and observe the cell lesions caused by virus infection. Finally, draw the virus growth curve based on the virus titer at different time points after virus infection.
[0141] The results showed that after rFJzz1-F5, rFJzz1-F10 and rFJzz1-F20 viruses infected Vero cells, typical syncytial-like CPE appeared. Using the anti-PEDV N protein mouse monoclonal antibody prepared in this laboratory as the primary antibody, specific green fluorescence could be observed under an inverted fluorescence microscope, which was similar to the parental virus. The plaque test results showed that the plaque morphology of rFJzz1-F5, rFJzz1-F10 and rFJzz1-F20 was similar in size to the parental virus, with no significant difference. The results of the multi-step growth curve showed that the proliferation ability of rFJzz1-F5, rFJzz1-F10 and rFJzz1-F20 viruses was similar, and the highest virus titer was reached 24 hours after infection, but the highest virus titer increased slightly with the increase in generations (see Fig. 9 ).
[0142] The foregoing description of specific exemplary embodiments of the present invention is for the purpose of illustration and demonstration. These descriptions are not intended to limit the present invention to the precise form disclosed, and it is clear that many changes and variations can be made based on the above teachings. The purpose of selecting and describing the exemplary embodiments is to explain the specific principles of the present invention and its practical application, so that those skilled in the art can realize and utilize various different exemplary embodiments of the present invention and various different selections and changes. The scope of the present invention is intended to be limited by the claims and their equivalents.
Claims
1. A reverse genetics system for rescuing porcine epidemic diarrhea virus FJzz1 strain based on in vitro ligation, characterized in that The reverse genetics system comprises: (a) The modified vector pBSK; (b) Full-length fragment of PEDV genome; (c) A helper plasmid containing the N gene of porcine epidemic diarrhea virus; wherein the vector pBSK is obtained by modifying the multiple cloning site region between KpnI and SacI in the plasmid pBluescriptIISK(+), wherein the order of the modified multiple cloning site region is KpnI-SacII-BamHI-AvrII-PacI-XmaI-BlpI-AgeI-AscI-SacI; the full length of the PEDV genome is divided into 7 segments of different sizes, A, B, C, D, E, F and G, and the 7 segments are connected by 6 specific restriction endonuclease sites, namely BamHI, AvrⅡ, PacⅠ, XmaI, BlpⅠ and AgeⅠ; a T7 prokaryotic promoter is added to the 5' end of the A segment; a 23 poly A tail is added to the 3' end of the G segment; the restriction endonuclease site XmaI between the D segment and the E segment is I is a genetic maker introduced by silent mutation; the seven segments of the full length of the PEDV genome are integrated into three large segments, AB, CDE and FG, and a T7 prokaryotic promoter is added to the 5' end of the AB segment for subsequent in vitro transcription; at the same time, in order to improve the packaging efficiency of the rescued virus, a tail consisting of 23 poly A is added to the 3' end of the FG segment; Among them, the specific sequence of the N gene is Genbank number: MK288006.1, corresponding to the specific position 26376-27701nt; The primers for amplifying the PEDV genome are:
2. A method for rescuing porcine epidemic diarrhea virus FJzz1 strain, characterized in that: The following steps are involved: The recombinant expression vector as claimed in claim 1 and the auxiliary plasmid are co-transfected into host cells, and after the cells become cytopathic, they are repeatedly frozen and thawed and the supernatant is collected to obtain the rescued virus.
3. The rescued virus obtained by the method of claim 2.
4. The use of the rescued virus as claimed in claim 3, characterized in that: The application is: Application in the creation of a new marker vaccine for porcine epidemic diarrhea virus, rapid identification and differentiation between vaccine strain immunity and wild strain infection; Application in screening of drugs against porcine epidemic diarrhea virus; Application in the study of the pathogenesis of porcine epidemic diarrhea virus; or in the study of the gene function of porcine epidemic diarrhea virus; The applications are for non-disease diagnosis and treatment purposes.
Citation Information
Patent Citations
Method for constructing swine-borne BVDV-22 strain infectious cDNA (complementary deoxyribonucleic acid) clone and application thereof
CN106318975A
Method for constructing full-length infectious cDNA [complementary DNA (deoxyribonucleic acid)] of PEDV JS2008 (porcine epidemic diarrhea virus JS2008) strains and application of full-length infectious cDNA
CN107267532A
Reverse genetic system for rescuing PEDV (porcine epidemic diarrhea virus) ZJU / G2 / 2013 strain based on DNA (deoxyribonucleic acid) plasmid transfection
CN111471709A
Porcine epidemic diarrhea virus vaccine strain and preparation method thereof
CN112779228A
Porcine epidemic diarrhea virus infectious cDNA clone and construction method and application thereof
CN114395568A
